Literature DB >> 12893437

Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth.

Michihiro Hirama1, Fumiyuki Takahashi, Kazuhisa Takahashi, Shigeru Akutagawa, Kazue Shimizu, Sanae Soma, Yuri Shimanuki, Kazuto Nishio, Yoshinosuke Fukuchi.   

Abstract

Angiogenesis, which is essential for tumor growth, is regulated by various angiogenic factors. Osteopontin (OPN) is expressed in various human tumors and is postulated to be involved in tumor progression. We have recently reported that culture medium with murine neuroblastoma C1300 cells transfected with OPN gene significantly stimulates human umbilical vein endothelial cell migration and induces neovascularization in mice by dorsal air sac assay. However, the effect of OPN on tumorigenesis as an angiogenic factor remains to be clarified. In this study, we injected the OPN-transfected C1300 cells and control cells into the nude mice subcutaneously. OPN-overexpressing C1300 cells significantly formed rapidly growing tumor as compared to the control cells in mice, although in vitro and in vivo cell growth rates were similar. In vivo tumorigenecity of these cells correlated with the amount of secreted OPN protein. In addition, neovascularization of OPN-transfected tumor was significantly increased in comparison with those of control cells by immunohistochemistry for CD31. In vitro chemoinvasiveness and gene expression of proteases including uPA, MMP2, 9, MT1-MMP, and cathepsin B, D, L, were not different between OPN-transfected and control cells determined with matrigel invasion assay and cDNA expression macroarray, respectively. Conclusively, these results strongly imply that OPN plays an important role in tumor growth through the enhancement of angiogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893437     DOI: 10.1016/s0304-3835(03)00286-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  24 in total

1.  Elevated osteopontin expression and proliferative/apoptotic ratio in the colorectal adenoma-dysplasia-carcinoma sequence.

Authors:  Gábor Valcz; Ferenc Sipos; Tibor Krenács; Jeannette Molnár; Arpád V Patai; Katalin Leiszter; Kinga Tóth; Norbert Solymosi; Orsolya Galamb; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2010-03-27       Impact factor: 3.201

2.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

3.  Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma.

Authors:  Maryam Mardani; Azadeh Andisheh-Tadbir; Bijan Khademi; Mohammad Javad Fattahi; Shapour Shafiee; Maryam Asad-Zadeh
Journal:  Tumour Biol       Date:  2013-12-14

4.  Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435.

Authors:  Lalita A Shevde; Rajeev S Samant; Jason C Paik; Brandon J Metge; Ann F Chambers; Graham Casey; Andra R Frost; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2006-07-09       Impact factor: 5.150

Review 5.  Inflammatory stress and sarcomagenesis: a vicious interplay.

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2013-08-27       Impact factor: 3.667

6.  Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.

Authors:  Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Hellmuth-A Meyer; Stefan A Loening; Klaus Jung
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

7.  Progesterone and placentation increase secreted phosphoprotein one (SPP1 or osteopontin) in uterine glands and stroma for histotrophic and hematotrophic support of ovine pregnancy.

Authors:  Kathrin A Dunlap; David W Erikson; Robert C Burghardt; Frank J White; Kristey M Reed; Jennifer L Farmer; Thomas E Spencer; Ronald R Magness; Fuller W Bazer; Kayla J Bayless; Greg A Johnson
Journal:  Biol Reprod       Date:  2008-07-30       Impact factor: 4.285

8.  Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity.

Authors:  Yuri Kim; Qun Lin; Daniel Zelterman; Zhong Yun
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

9.  Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer.

Authors:  Kannan Rangiah; Montri Tippornwong; Vineet Sangar; David Austin; Marie-Pier Tétreault; Anil K Rustgi; Ian A Blair; Kenneth H Yu
Journal:  J Proteome Res       Date:  2009-11       Impact factor: 4.466

10.  Release characteristics and osteogenic activity of recombinant human bone morphogenetic protein-2 grafted to novel self-assembled poly(lactide-co-glycolide fumarate) nanoparticles.

Authors:  Angel E Mercado; Junyu Ma; Xuezhong He; Esmaiel Jabbari
Journal:  J Control Release       Date:  2009-08-20       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.